Riviciclib
As of the edition of 20 October 2026, Riviciclib is a small molecule: went quiet in 2014; acts on CDK1, CDK4 and CDK9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Small molecule
- Registered trials
- 10, 3 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product3 company-target rows are on route A because of Riviciclib.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 7 | 6 | 0 | 1 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Piramal Enterprises | Lead sponsor of trials | 2005 to now |